SG11201610446XA - Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau - Google Patents

Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau

Info

Publication number: SG11201610446XA
Authority: SG; Singapore
Prior art keywords: microtubule; antigen; antibodies; specifically bind; binding fragments
Prior art date: 2014-06-26

Application number

SG11201610446XA

Inventor

Jehangir Wadia

Gabriel Pascual

Robert Anthony Williamson

Katarina Radosevic

Jaap Goudsmit

Original Assignee

Janssen Vaccines & Prevention Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-06-26

Filing date

2015-06-26

Publication date

2017-01-27

2015-06-26 Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv

2017-01-27 Publication of SG11201610446XA publication Critical patent/SG11201610446XA/en

Links

102100040243 Microtubule-associated protein tau Human genes 0.000 title 1
101710115937 Microtubule-associated protein tau Proteins 0.000 title 1
239000000427 antigen Substances 0.000 title 1
102000036639 antigens Human genes 0.000 title 1
108091007433 antigens Proteins 0.000 title 1
239000012634 fragment Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Analytical Chemistry (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Epidemiology (AREA)
Mycology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

SG11201610446XA 2014-06-26 2015-06-26 Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau SG11201610446XA (en)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US201462017789P	2014-06-26	2014-06-26
US201462017746P	2014-06-26	2014-06-26
US201462017812P	2014-06-26	2014-06-26
US201462017807P	2014-06-26	2014-06-26
EP14179739		2014-08-04
EP14179706		2014-08-04
EP14179719		2014-08-04
EP14179699		2014-08-04
PCT/EP2015/064529 WO2015197820A1 (en)	2014-06-26	2015-06-26	Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau

Publications (1)

Publication Number	Publication Date
SG11201610446XA true SG11201610446XA (en)	2017-01-27

Family

ID=54937409

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201610446XA SG11201610446XA (en)	2014-06-26	2015-06-26	Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
SG11201610459XA SG11201610459XA (en)	2014-06-26	2015-06-26	Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG11201610459XA SG11201610459XA (en)	2014-06-26	2015-06-26	Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau

Country Status (13)

Country	Link
US (2)	US10301379B2 (en)
EP (3)	EP3486256A3 (en)
JP (2)	JP2017521063A (en)
KR (2)	KR20170023151A (en)
CN (2)	CN107074965B (en)
AU (3)	AU2015279086B2 (en)
BR (2)	BR112016029579A2 (en)
CA (2)	CA2952741A1 (en)
EA (2)	EA035530B1 (en)
NZ (2)	NZ727020A (en)
SG (2)	SG11201610446XA (en)
WO (2)	WO2015197823A2 (en)
ZA (1)	ZA201608811B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR102313513B1 (en)	2013-03-13	2021-10-15	프로테나 바이오사이언시즈 리미티드	Tau immunotherapy
SG11201610446XA (en)	2014-06-26	2017-01-27	Janssen Vaccines & Prevention Bv	Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
ZA201608812B (en)	2014-06-26	2019-08-28	Janssen Vaccines & Prevention Bv	Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
DK3452507T3 (en)	2016-05-02	2022-11-14	Prothena Biosciences Ltd	TAU IMMUNOTHERAPY
US10889638B2 (en)	2016-05-02	2021-01-12	Prothena Biosciences Limited	Antibodies recognizing tau
US10364286B2 (en) *	2016-12-22	2019-07-30	H. Lundbeck A/S	Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
MX2019009817A (en)	2017-02-17	2019-11-21	Denali Therapeutics Inc	Anti-tau antibodies and methods of use thereof.
CN110418804A (en) *	2017-03-28	2019-11-05	扬森疫苗与预防公司	Binding molecules that specifically bind to tau
US20210147481A1 (en) *	2017-04-21	2021-05-20	Ohio University	Peptide-based inhibitors of mark family proteins
AU2018263935B2 (en)	2017-05-02	2024-09-26	Prothena Biosciences Limited	Antibodies recognizing tau
PH12020551216A1 (en)	2017-10-16	2024-06-24	Eisai R&D Man Co Ltd	Anti-tau antibodies and uses thereof
EA202091012A1 (en)	2017-10-25	2020-08-27	Янссен Фармасьютикалз, Инк.	COMPOSITIONS OF PHOSPHORYLATED TAU PEPTIDES AND THEIR APPLICATION
JP2021505142A (en)	2017-12-04	2021-02-18	ヤンセンファッシンズアンドプリベンションベーフェーＪａｎｓｓｅｎＶａｃｃｉｎｅｓ＆ＰｒｅｖｅｎｔｉｏｎＢ．Ｖ．	A binding molecule that specifically binds to tau
US11629183B2 (en)	2017-12-29	2023-04-18	University Of Florida Research Foundation, Inc.	Monoclonal antibodies targeting microtubule-binding domain of tau protein and methods of detecting tau protein in vivo
JP2021512602A (en)	2018-02-01	2021-05-20	ヤンセンファッシンズアンドプリベンションベーフェーＪａｎｓｓｅｎＶａｃｃｉｎｅｓ＆ＰｒｅｖｅｎｔｉｏｎＢ．Ｖ．	A binding molecule that specifically binds to tau
WO2019171258A1 (en)	2018-03-05	2019-09-12	Janssen Pharmaceutica Nv	Assays to detect neurodegeneration
EA202092088A1 (en) *	2018-03-05	2020-11-13	Янссен Фармацевтика Нв	ANTI-PHF-TAU ANTIBODIES AND THEIR APPLICATION
WO2019175735A1 (en) *	2018-03-11	2019-09-19	Koorosh Shahpasand	Conformation-independent antibodies against neurotoxic tau proteins
EA202190807A1 (en) *	2018-10-19	2021-08-06	Янссен Вэксинс Энд Превеншн Б.В.	ANTIBODIES TO SYNUCLEINE
KR20210125048A (en)	2019-02-08	2021-10-15	에이씨 이뮨 에스.에이.	Safe Administration of Phosphorylated Tau Peptide Vaccine
AU2020231366A1 (en)	2019-03-03	2021-08-12	Prothena Biosciences Limited	Antibodies recognizing tau
JP7617852B2 (en)	2019-04-24	2025-01-20	ヤンセンファーマシューティカルズ，インコーポレーテッド	Heterologous administration of tau vaccine
GB201909393D0 (en) *	2019-06-28	2019-08-14	Gen2 Neuroscience Ltd	Tau epitope and binding molecules
GB2585252A (en)	2019-07-05	2021-01-06	Gen2 Neuroscience Ltd	Tau epitope and binding molecules
KR20220014531A (en) *	2020-07-29	2022-02-07	(주)메디톡스	Heterodimeric Fc fusion proteins, and related compositions, uses and methods
US20250034559A1 (en)	2021-11-17	2025-01-30	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of tau-related disorders
IL319121A (en)	2022-09-15	2025-04-01	Voyager Therapeutics Inc	Tau binding compounds
WO2025122634A1 (en)	2023-12-05	2025-06-12	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of tau-related disorders

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
DK0463151T3 (en)	1990-01-12	1996-07-01	Cell Genesys Inc	Generation of xenogenic antibodies
GB9316727D0 (en)	1993-08-12	1993-09-29	Inst Of Psychiatry	Models of alzheimers's disease
US5585250A (en)	1993-08-20	1996-12-17	The United States Of America As Represented By The Department Of Health & Human Services	Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies
ES2235225T3 (en)	1996-02-14	2005-07-01	Biomerieux B.V.	ISOLATION OF NUCLEIC ACIDS OF SIMPLE RAMALLES.
US6881537B1 (en)	1997-08-08	2005-04-19	Biomerieux, B.V.	Nucleic acid sequences that can be used as primers and probes in the amplification and detection of all subtypes of HIV-1
WO2001031046A1 (en)	1999-10-26	2001-05-03	International Aids Vaccine Initiative	Invasive bacterial vectors for expressing alphavirus replicons
US7425437B2 (en)	1999-11-26	2008-09-16	Crucell Holland B.V.	Vaccines against West Nile Virus
US20050019759A1 (en)	2000-09-08	2005-01-27	Jaap Goudsmit	Attenuated HIV strains and uses thereof
US20030008275A1 (en)	2000-09-08	2003-01-09	Jaap Goudsmit	Attenuated HIV strains and use thereof
WO2003017918A2 (en)	2001-08-24	2003-03-06	Universität Zürich	A method of inducing the formation of neurofibrillary tangles in transgenic animals
WO2004111081A2 (en)	2003-06-13	2004-12-23	Crucell Holland B.V.	Antigenic peptides of sars coronavirus and uses thereof
WO2005084158A2 (en)	2003-06-20	2005-09-15	The Regents Of The University Of California	Polypeptide transduction and fusogenic peptides
WO2005012337A2 (en)	2003-07-15	2005-02-10	Crucell Holland B.V.	Antigenic peptides of sars coronavirus and uses thereof
WO2005012338A1 (en)	2003-07-21	2005-02-10	Crucell Holland B.V.	Antigenic peptides of sars coronavirus and uses thereof
CA2531684C (en)	2003-07-22	2014-03-11	Crucell Holland B.V.	Binding molecules against sars-coronavirus and uses thereof
WO2005023849A2 (en)	2003-09-04	2005-03-17	Crucell Holland B.V.	Antigenic peptides of rabies virus and uses thereof
US20080027025A1 (en)	2004-08-27	2008-01-31	The Regents Of The University Of California	Protection From And Treatment Of Prion Protein Infection
WO2006037038A1 (en)	2004-09-27	2006-04-06	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Optimized vaccines to provide protection against ebola and other viruses
ES2371175T3 (en)	2004-10-14	2011-12-28	Crucell Holland B.V.	SENSITIZATION VACCINES / REINFORCEMENT OF MALARIA.
WO2006051091A1 (en)	2004-11-11	2006-05-18	Crucell Holland B.V.	Compositions against sars-coronavirus and uses thereof
KR101255870B1 (en)	2004-11-16	2013-04-17	아에라스 글로벌 티비 백신 파운데이션	Multivalent vaccines comprising recombinant viral vectors
US8241863B2 (en)	2005-03-10	2012-08-14	The Regents Of The University Of California	Identification of an evolutionarily conserved pathway mediating transrepression of inflammatory response genes by nuclear receptors
WO2007095152A2 (en)	2006-02-10	2007-08-23	The Regents Of The University Of California	TRANSDUCIBLE DELIVERY OF sIRNA BY dsRNA BINDING DOMAIN FUSIONS TO PTD/CPPS
US20090110695A1 (en)	2006-03-27	2009-04-30	Menzo Jans Emko Havenga	Compositions Comprising a Recombinant Adenovirus and an Adjuvant
LT2436696T (en) *	2007-01-05	2017-08-25	University Of Zurich	Anti-beta-amyloid antibody and uses thereof
EP2185592B1 (en) *	2007-09-13	2013-01-23	University Of Zurich Prorektorat Forschung	Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
WO2010033229A2 (en)	2008-09-22	2010-03-25	Calmune Corporation	Methods and vectors for display of molecules and displayed molecules and collections
US20100081575A1 (en)	2008-09-22	2010-04-01	Robert Anthony Williamson	Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules
WO2010129033A2 (en)	2009-04-29	2010-11-11	Calmune Corporation	Modified antibodies for passive immunotherapy
PT2248825E (en)	2009-05-04	2013-01-07	Ribovax Biotechnologies Sa	Antigen binding fragments of an antibody for use in treating and diagnosing ocular diseases
CA3239368A1 (en) *	2009-06-10	2010-12-16	New York University	Immunological targeting of pathological tau proteins
IN2012DN01328A (en)	2009-08-13	2015-06-05	Crucell Holland Bv
US9181585B2 (en)	2009-09-17	2015-11-10	Cy O'connor Erade Village Foundation	Methods of genotyping livestock
WO2011035205A2 (en)	2009-09-18	2011-03-24	Calmune Corporation	Antibodies against candida, collections thereof and methods of use
EP2591000B1 (en)	2010-07-09	2017-05-17	Janssen Vaccines & Prevention B.V.	Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
WO2012041669A1 (en)	2010-09-27	2012-04-05	Crucell Holland B.V.	Heterologous prime boost vaccination regimen against malaria
WO2012049570A1 (en) *	2010-10-11	2012-04-19	Panima Pharmaceuticals Ag	Human anti-tau antibodies
EP2655604B1 (en)	2010-12-14	2018-05-09	The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services	Adenovirus serotype 26 and serotype 35 filovirus vaccines
WO2012175692A1 (en) *	2011-06-22	2012-12-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti-axl antibodies and uses thereof
UA115657C2 (en)	2011-09-19	2017-12-11	Аксон Ньюросайєнс Сє	Isolated antibody that binds to one or more epitopes SAU, a pharmaceutical composition that contains it, METHOD OF TREATMENT AND DIAGNOSIS WAY BASED Alzheimer isolated antibody
AR092779A1 (en)	2011-10-07	2015-05-06	Ac Immune Sa	PHARMACEUTICAL COMPOSITION THAT INCLUDES ANTIBODIES THAT JOIN TAU PROTEIN CONFORMERS
WO2013074501A1 (en)	2011-11-14	2013-05-23	Crucell Holland B.V.	Heterologous prime-boost immunization using measles virus-based vaccines
MX357009B (en)	2011-11-28	2018-06-22	Crucell Holland Bv	Influenza virus vaccines and uses thereof.
PL2794654T3 (en) *	2011-12-20	2019-11-29	Janssen Biotech Inc	Anti-phf-tau antibodies and their uses
US20130236494A1 (en)	2012-03-06	2013-09-12	Crucell Holland B.V.	Vaccination against influenza
US9125870B2 (en)	2012-03-22	2015-09-08	Crucell Holland B.V.	Vaccine against RSV
KR102494798B1 (en) *	2012-07-03	2023-02-06	워싱턴 유니버시티	Antibodies to tau
SG11201504822VA (en) *	2012-12-21	2015-07-30	Biogen Idec Internat Neuroscience Gmbh	Human anti-tau antibodies
WO2014170258A1 (en)	2013-04-15	2014-10-23	Crucell Holland B.V.	Human antibodies binding to rsv g proteins
KR102201554B1 (en)	2013-04-15	2021-01-12	얀센 백신스 앤드 프리벤션 비.브이.	Human antibodies binding to rsv g protein
CA2913859C (en)	2013-05-30	2021-11-30	Crucell Holland B.V.	Influenza virus vaccines and uses thereof
SG11201610446XA (en)	2014-06-26	2017-01-27	Janssen Vaccines & Prevention Bv	Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau

2015
- 2015-06-26 SG SG11201610446XA patent/SG11201610446XA/en unknown
- 2015-06-26 CN CN201580034105.1A patent/CN107074965B/en not_active Expired - Fee Related
- 2015-06-26 CA CA2952741A patent/CA2952741A1/en not_active Abandoned
- 2015-06-26 US US15/321,680 patent/US10301379B2/en not_active Expired - Fee Related
- 2015-06-26 EA EA201692539A patent/EA035530B1/en not_active IP Right Cessation
- 2015-06-26 KR KR1020177002193A patent/KR20170023151A/en not_active Abandoned
- 2015-06-26 EP EP18199818.8A patent/EP3486256A3/en not_active Withdrawn
- 2015-06-26 SG SG11201610459XA patent/SG11201610459XA/en unknown
- 2015-06-26 EA EA201692394A patent/EA036307B1/en not_active IP Right Cessation
- 2015-06-26 EP EP15731936.9A patent/EP3160999B1/en active Active
- 2015-06-26 AU AU2015279086A patent/AU2015279086B2/en not_active Ceased
- 2015-06-26 JP JP2016575196A patent/JP2017521063A/en active Pending
- 2015-06-26 BR BR112016029579A patent/BR112016029579A2/en not_active Application Discontinuation
- 2015-06-26 CN CN201580034112.1A patent/CN107074935B/en not_active Expired - Fee Related
- 2015-06-26 NZ NZ727020A patent/NZ727020A/en not_active IP Right Cessation
- 2015-06-26 CA CA2952745A patent/CA2952745A1/en not_active Abandoned
- 2015-06-26 US US15/321,918 patent/US10400034B2/en not_active Expired - Fee Related
- 2015-06-26 JP JP2016575162A patent/JP6641305B2/en not_active Expired - Fee Related
- 2015-06-26 KR KR1020177001941A patent/KR20170023124A/en not_active Ceased
- 2015-06-26 EP EP15731934.4A patent/EP3160998B1/en active Active
- 2015-06-26 WO PCT/EP2015/064533 patent/WO2015197823A2/en active Application Filing
- 2015-06-26 AU AU2015279089A patent/AU2015279089B2/en not_active Ceased
- 2015-06-26 NZ NZ727024A patent/NZ727024A/en not_active IP Right Cessation
- 2015-06-26 BR BR112016030183A patent/BR112016030183A2/en not_active Application Discontinuation
- 2015-06-26 WO PCT/EP2015/064529 patent/WO2015197820A1/en active Application Filing
2016
- 2016-12-21 ZA ZA2016/08811A patent/ZA201608811B/en unknown
2020
- 2020-12-30 AU AU2020294348A patent/AU2020294348A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NZ727020A (en)	2022-02-25
CA2952741A1 (en)	2015-12-30
EA201692394A1 (en)	2017-04-28
AU2020294348A1 (en)	2021-02-25
CN107074965A (en)	2017-08-18
WO2015197820A1 (en)	2015-12-30
KR20170023151A (en)	2017-03-02
CN107074965B (en)	2021-08-03
CN107074935B (en)	2021-08-03
SG11201610459XA (en)	2017-01-27
AU2015279089B2 (en)	2021-01-28
AU2015279086A1 (en)	2016-12-15
EP3160998B1 (en)	2019-08-21
US10400034B2 (en)	2019-09-03
CN107074935A (en)	2017-08-18
EA201692539A1 (en)	2017-04-28
BR112016029579A2 (en)	2017-08-22
EA035530B1 (en)	2020-06-30
JP2017520254A (en)	2017-07-27
EP3486256A3 (en)	2019-08-28
CA2952745A1 (en)	2015-12-30
EA036307B1 (en)	2020-10-23
JP2017521063A (en)	2017-08-03
ZA201608811B (en)	2022-09-28
NZ727024A (en)	2022-02-25
KR20170023124A (en)	2017-03-02
EP3160999A2 (en)	2017-05-03
WO2015197823A3 (en)	2016-02-18
JP6641305B2 (en)	2020-02-05
AU2015279089A1 (en)	2016-12-15
EP3160998A1 (en)	2017-05-03
US20170152307A1 (en)	2017-06-01
BR112016030183A2 (en)	2017-11-14
EP3486256A2 (en)	2019-05-22
US20170210787A1 (en)	2017-07-27
AU2015279086B2 (en)	2021-01-28
EP3160999B1 (en)	2018-11-28
WO2015197823A2 (en)	2015-12-30
US10301379B2 (en)	2019-05-28

Publication	Publication Date	Title
ZA201608811B (en)	2022-09-28	Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
ZA202003742B (en)	2022-08-31	Anti-lag3 antibodies and antigen-binding fragments
ZA202003133B (en)	2025-06-25	Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof
ZA201707138B (en)	2022-11-30	Anti-ceacam6 antibodies and uses thereof
IL246693B2 (en)	2023-03-01	Antibody molecules to tim-3 and uses thereof
ZA201704943B (en)	2019-01-30	Antibodies to tau and uses thereof
LT3166970T (en)	2021-05-10	IMPROVED A-BETA PROTOFIBRILE BINDING ANTIBODIES
IL247488A0 (en)	2016-11-30	Vl antigen binding proteins exhibiting distinct binding characteristics
IL247590A0 (en)	2016-11-30	Bi-specific antibodies and uses thereof
EP3131574A4 (en)	2018-01-03	Antigen binding proteins that bind wisp1
ZA201701941B (en)	2018-05-30	Antigen binding proteins that bind cxcr3
EP3209686A4 (en)	2018-03-07	Monoclonal anti-gpc-1 antibodies and uses thereof
ZA201608812B (en)	2019-08-28	Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
GB201415714D0 (en)	2014-10-22	Antibodies and antigen binding fragments thereof
HK1236963A1 (en)	2018-04-06	Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
HK1236964A1 (en)	2018-04-06	Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
HK1233533A1 (en)	2018-02-02	Antigen binding proteins that bind wisp1
HK1234073A1 (en)	2018-02-09	Anti-hepatitis c antibodies and antigen binding fragments thereof